Sun Pharma Announces Pre-Clinical Data on GL0034

Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office : SPARC, Tandalja, Vadodara – 390 020. India Reaching People. Touching Lives. FOR IMMEDIATE RELEASE Sun Pharma Announces Pre-Clinical Data on GL0034, an Experimental NCE to Treat Type 2 Diabetes and Obesity Mumbai, India, June 24, 2020 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN. BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “S un Pharma” including its subsidiaries and/or associate companies) today announced an update on t he pre-clinical molecule, for which a disclosure was made in the Q1FY20 results press release. The experimental New Chemical Entity (NCE), GL0034 is a long-acting GLP-1R (Glucagon-Like Peptide-1 Recep tor) agonist. Such agonists are used to treat patients with type 2 diabetes, including short-acting, intermediate-acting, and long-acting therapies 1. The pre-clinical data for GL0034 was recently prese nted at the American Diabetes Association (ADA) Virtual 80 th Scientific Sessions. GL0034 has been developed int ernally by Sun Pharma’s High Impact Innovations – Sustainable Health Solutions (HISHS) Discovery Team. Pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters evaluated, viz. glucose reduction, decrease in HbA1c (an important marker for clinical efficacy), augmented insulin secretion, lowering of glucagon level and a marked and meaningful reduction in triglyceride levels. Al l these outcomes with GL0034 were found to be higher or significant to the currently marketed once a week GLP-1R agonists compared in the study. Yet another important feature in diabetes treatment is weight management. GL0034 induced a larger body weight reduction, 1.9x and 3.8x times higher than the two different standard once a week GLP-1R agonist drugs compared in the study, with similar food consumption. Dilip Shanghvi, Managing Director, Sun Pharma said, “We are excited by the robust pre-clinical data fo r GL0034 and believe that it has significant potentia l. We look forward to validating this data in human clinical trials.” Sun Pharma is planning to initiate Phase-1 clinical trials for GL0034 by Q3FY21. Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office : SPARC, Tandalja, Vadodara – 390 020. India Reaching People. Touching Lives. About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050) Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a ski lled team enables it to deliver high-quality produc ts, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presen ce is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory a gencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellenc e through innovation supported by strong R&D capabilities acr oss multiple R&D centers, with investments of appro ximately 7% of annual revenues in R&D. For further informati on, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live . Disclaimer Statements in this “Document” describing the Compan y’s objectives, projections, estimates, expectation s, plans or predictions or industry conditions or events may be “forward lo oking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. References 1. Hinnen, D. Diabetes Spectr. 2017; 30:202–10. Contacts: Investors: Media: Nimish Desai Gaurav Chugh Tel +91 22 4324 4324, Xtn 2778 Tel +91 22 4324 432 4, Xtn 5373 Tel Direct +91 22 4324 2778 Tel Direct +91 22 4324 5373 Mobile +91-98203 30182 Mobile +91 98104 71414 E mail [email protected] E mail gaurav.ch [email protected]

The release as fetched from its publisher. sunpharma.com ↗